A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder.


Journal Article

OBJECTIVE: Features of bipolarity in a major depressive disorder sample were used to define a "bipolar spectrum disorder" population for treatment with a neuroleptic agent, ziprasidone. METHODS: Forty-nine acutely depressed patients were randomized to ziprasidone-washout-placebo or placebo-washout-ziprasidone in this double-blind, prospective, 13-week crossover trial. All patients met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria for a major depressive episode and were positive for at least 3 predictors of bipolarity: family history of bipolar disorder, antidepressant-induced mania, highly recurrent depressive episodes (>5), atypical depression, early onset of depression (

Full Text

Duke Authors

Cited Authors

  • Patkar, AA; Pae, C-U; Vöhringer, PA; Mauer, S; Narasimhan, M; Dalley, S; Loebel, A; Masand, PS; Ghaemi, SN

Published Date

  • June 2015

Published In

Volume / Issue

  • 35 / 3

Start / End Page

  • 319 - 323

PubMed ID

  • 25882763

Pubmed Central ID

  • 25882763

Electronic International Standard Serial Number (EISSN)

  • 1533-712X

Digital Object Identifier (DOI)

  • 10.1097/JCP.0000000000000323


  • eng

Conference Location

  • United States